Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 801 - 850 out of 6,875

Document Document Title
WO/2008/065493A1
The invention relates to the compounds of formula (I), or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions contai...  
WO/2008/065181A2
Pyran derivatives of general formula (I) wherein Y is a 5-, 6- or 7-membered ring, preferably a 5-membered ring, methyl or ethyl mono- or polysubstituted, and optionally unsaturated, and R1, R2, R3, R4 are, each independently, a hydrogen...  
WO/2008/055870A1
Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to...  
WO/2008/053360A2
The invention relates to portable albumin binders, which are useful for improving the pharmacokinetic properties of diagnostic or therapeutic agents, in particular increasing the blood circulation time and/or the tissue penetration capac...  
WO/2008/052930A2
New process for the preparation of 4-(4-alkoxyphenyl)tetrahydropyrane derivatives used in the preparation of 4-alkoxy-7-(tetrahydropyran-4-yl)-benzothiazol-2-ylamine and derivatives.  
WO/2008/053206A2
A process for the preparation of L-gluconic acid or a salt thereof, comprises treating an aqueous solution of 6-bromo-6-deoxy-2,3-anhydro-D-manno-1,4-lactone with a base at a pH of at least 12 and at a temperature of 45 to 6O0C to obtain...  
WO/2008/044339A1
It is intended to provide a DNA synthesis inhibitor in retinal vascular endothelial cells, and a therapeutic agent and a preventive agent for an intraocular disease associated with an intraocular disease. The invention is based on Exampl...  
WO/2008/042688A2
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.  
WO/2008/037603A1
The invention relates to a process for extracting phloridzine from apple seeds, comprising the steps of: production of a first concentrated extract from said seeds; liquid-liquid extraction of said phloridzine from said concentrated extr...  
WO/2008/039645A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2008/034859A1
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according...  
WO/2008/036216A1
The present invention is directed to aspartic protease inhibitors represented by the following structural formula; or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions compr...  
WO/2008/036247A1
The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions c...  
WO/2008/034511A1
The invention relates to claimed indane compounds of formula (I), in which R1, A1, A2, B, Z1, Z2, Z3, X1, X2, m and n are defined as per claim 1. Said compounds have at least one tetrahydropyran ring (B) and are suitable for use as compo...  
WO/2008/032156A1
Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described her...  
WO/2008/026140A2
The invention relates to a malodor counteractancy or counteracting (MOC) method that resorts to the use of specific malodor counteracting (MOC) mixtures of fragrance ingredients. More particularly, the invention relates to new MOC compos...  
WO/2008/024302A2
Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer inductio...  
WO/2008/024963A1
Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein A, Q1, Q2, Q3, R3, R4, R5, R0, m, and p are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related ...  
WO/2008/024961A1
Disclosed are compounds and pharmaceutically acceptable salts of Formula (I), wherein A, Q1, Q2, Q3, R3, and R4 are as defined herein. Compounds of Formula (I) are heat-shock protein 90 (HSP-90) inhibitors, useful in the treatment of dis...  
WO/2008/019746A1
The invention relates to mesogenic tetrahydropyran compounds having at least four rings of the formula (I), in which R1, A1, A2, X1, L1, L2, m and n are each as defined in claim 1, and to a process for their preparation, to their use in ...  
WO/2008/019477A1
Compounds of formula (I) : wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.  
WO/2008/015240A1
The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinso...  
WO/2008/012372A1
The present invention provides an improved process for the manufacture of candesartan cilexetil form I. Further disclosed is a candesartan cilexetil preparation containing less than 0.15%, preferably less than 0.10%, of (+-)-1 -Hydroxyet...  
WO/2008/012371A1
The present invention provides processes for the preparation of amorphous and crystalline candesartan cilexetil with quality that complies to Ph.Eur./ICH Guidelines by an economical way using easy accessible substances and pure starting ...  
WO/2008/009118A1
Derivatives of drugs are provided, said derivatives comprising the H2S-releasing moiety 4-hydroxythiobenzamide that is either covalently linked to the drug or forms a salt with the drug. The compounds of the present invention exhibit enh...  
WO/2008/009897A1
The invention relates to the preparation of pregabalin and its opposite enantiomer, or a pharmaceutically-acceptable salt of either thereof, and to the intermediates used for their preparation.  
WO/2008/008442A1
Chemical syntheses and medical uses of novel modulators of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase and diastereomeric mixtures of isomers, individual diastereomers, pharmaceutically acceptable salts, solvates, or prodr...  
WO/2008/001752A1
Disclosed is a pharmaceutical composition for treatment or prevention of chronic obstructive pulmonary diseases. The pharmaceutical composition contains an HMG-CoA reductase inhibitor as an active ingredient.  
WO/2008/000407A1
The invention relates to compounds of the formula (I), in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as in...  
WO/2007/148648A1
Disclosed is a therapeutic or prophylactic agent for multiple sclerosis. The therapeutic or prophylactic agent comprises a glycine derivative having a specific structure (e.g., a compound [(E)-2-(2,6-dichlorobenzamide)-5-[4-(isopropyl-py...  
WO/2007/148676A1
Disclosed is a therapeutic or prophylactic agent for leukemia. The therapeutic or prophylactic agent comprises a glycine derivative having a specific structure such as a compound represented by the formula below [(E)-2-(2,6-dichlorobenza...  
WO/2007/145282A1
Disclosed is a therapeutic or prophylactic agent for allergic dermatitis. The therapeutic or prophylactic agent comprises a glycine derivative having a specific structure, such as a compound represented by the formula below (i.e., [(E)-2...  
WO/2007/144423A1
Antitumoral compounds of general formula (I) obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.  
WO/2007/136116A2
Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urin...  
WO/2007/136948A2
A hydrofluoroether compound comprises at least one five- or six-membered, perfluorinated heterocyclic ring, each ring comprising four or five ring carbon atoms and one or two catenated heteroatoms selected from divalent ether oxygen atom...  
WO/2007/136125A1
Disclosed are: a composition for inhibiting the transcription of an extracellular matrix gene, comprising a compound having a heterocyclic ring represented by the formula (I) and an inert carrier; and others.  
WO/2007/135565A2
The present invention is directed to molecules deriving from a 3-aryl-coumarine or 3-aryl-quinolin- 2-one and having potent anti-proliferative and/ or cytotoxic activity, especially against tumoral cells. The present invention also conce...  
WO/2007/128899A2
The invention concerns a C-glycoside compound of formula (I); wherein: n is equal to 1 or 2; Y represents H or halogen; X is an alkyl chain bearing at least one amino, amide, acid, ester, carbonyl, alcohol, aryl function or a carbonyl, e...  
WO/2007/128749A1
Glucopyranosyl- substituted, benzonitrile derivatives defined according to formula I, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof . The compounds according to the invention are suitable ...  
WO/2007/130783A2
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular v...  
WO/2007/125203A1
The invention relates to a gem-difluoride C-glycopeptide compound with formula I where n is an integer equal to 3 or 4, R represents a hydrogen atom, an alkyl, benzyl, acetyl, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsi...  
WO/2007/125832A1
A new action of Helipyrone A is now found. As a useful application of Helipyrone A, the following agent is disclosed: a singlet oxygen scavenger, an anti-skin-aging agent, an anti-wrinkle agent, an anti-sagging agent, an agent for improv...  
WO/2007/116015A1
The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cos...  
WO/2007/116013A1
The present invention relates to novel galactose derivatives of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmeti...  
WO/2007/099111A1
A hydrogenation process for the conversion of a reactant selected from the group consisting of a carboxylic acid having a carbonyl group and an ester of a carboxylic acid having a carbonyl group to form a carboxylic acid or an ester with...  
WO/2007/100351A2
Novel processes for the preparation of simvastatin and intermediates of such processes. Preferred embodiments include the preparation of lovastatin amides, protected lovastatin amide derivatives, simvastatin dihydroxy acid amide derivati...  
WO/2007/097406A1
Disclosed is a method for converting a carbon cluster into a hydrophilic carbon cluster without greatly changing the characteristics of the carbon cluster. Also disclosed are a hydrophilic carbon cluster having a structure wherein a subs...  
WO/2007/096753A2
The present invention discloses a solid compound of silylated simvastatin having formula (I). Said compound of Formula (I) is prepared by hydrolyzing lovastatin to diol lactone; converting said diol lactone to silylated lactone; and acyl...  
WO/2007/093610A1
Glucopyranosyl-substituted benzonitrile derivative of formula (I) are disclosed, wherein R3 denotes hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, 3-methyl-but-1-...  
WO/2007/095613A2
The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and / or for preventing neuron death or damage following brain, head and / or spi...  

Matches 801 - 850 out of 6,875